The global oligonucleotide CDMO market is poised for growth driven by the rising clinical pipeline of RNA-based therapies, increased mRNA therapeutic adoption, and biotech firms outsourcing to reduce ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57.97 each, according to the prospectus (PDF) filed with the HKEX exchange in ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie is entering a collaboration and license option deal ...

A Regeneron Pharmaceuticals drug that lowers levels of a disease-driving protein has met the goals of a pivotal test in the rare disease generalized myasthenia gravis. Based on these results, ...